Transcriptomic signatures related to inteferon (IFN)-γ signaling and activated T-cells are currently validated across tumors in patients treated with pembrolizumab.16,17 In addition, in the case of insufficient tumor-infiltrating lymphocytes (TILs) in a tumor, it is unlikely that PD-1/PD-L1 blockade would lead to a specific T-cell response18 despite PD-L1 expression. The gene discussed is CD274; the disease is neoplasm.